FDA Approves Denosumab for Multiple Myeloma

January 5, 2018 – The FDA has approved denosumab for the prevention of skeletal-related events (SREs) in patients with multiple myeloma, according to Amgen, the developer of the RANK ligand inhibitor. The approval is based on data from the phase III 482 study, which were presented at the 16th International Myeloma Workshop in New Delhi. In the trial, denosumab demonstrated noninferiority to zoledronic acid at delaying the time to the first SRE in patients with … (leggi tutto)